We review our data on the measurementof catecholamines and theirmetabolites in 19 patients with pheochromocytoma. All the assays were specific high-performance liquid chromatographic procedureswith electrothemical detection. The assay of fractionated metanephnnes was 100% sensitive. Normal values for both urinary norepinephnne and epinephrine were found in two asymptomatic patients with pheochromocytoma Normal values for 3-methoxy-4-hydroxymandelic acid (VMA) were found in two patients with pureepinephrinesecretingtumors and in one patient with multipleendocnne neoplasia type II. Plasma catecholamines were usually less increased than their urinary counterparts. We recommend the specificmeasurementof norepinephnneand epinephrine as the initial test for patients with suggestivesymptoms,and specificmeasurement of normetanephnneand metanephnne for patientsin whom an adrenal mass is incidentallyfound. We argue against the use of total metanephnnes, total catecholamines, and VMA pecause of their lack of diagnostic sensWvfty. 
The assays remained the same throughout the study period except for a minor change in the assay of VMA.
Materials and Methods

Sample Collection
Urine samples (24-h collections) were collected in polyethylene containers with 20 mL of 6 mol/L HC1 and stored at 4#{176}C. The completeness of the collection was verified by measuring the 24-h output of creatunine. The creatinunuria was <5 mmolJ24 h in cases 2 and 4, suggesting incomplete collections.
Because of the straightforward diagnosis of pheochromocytoma in both cases, however, no repeat collections were performed. In all other cases, creatininuria was between 7 and 17 mmol/24 h, amounts considered indicative of complete collections. Blood samples (10 mL) were taken in chilled tubes with lithium heparin anticoagulant, 30 min after venipuncture, from patients resting in the supine position. The plasma was separated from the cells within 30 miii after collection, and 50 L of 0.26 mauL sodium metabisulfite was added before storage at -20#{176}C. Sam-ples were usually analyzed 1 week after collection. 
ExtractionProcedures
Catecholstmineswere extracted from urine (1 mL) and from plasma (2 mL) according to a two-step purification scheme involving cation-exchange and alumina adsorption. Dihydroxybenzybimine was chosen as internal standard.
The detailed procedure and the chemicals used have been described previously (14).
VMA was extracted from 100 L of urine with 5 mL of ethyl acetate after addition of iso-VMA (100 L; 0.2 mmol/L in 0.1 mol/L HC1), 1 mL of 2 molIL HC1, and -2 g of NaC1. Two milliliters of the organic phase was evaporated under a stream of nitrogen at room temperature. The residue was dissolved in 2 mL of mobile phase and 20 L was injected. The recoveries of VMA and iso-VMA both averaged 87%. The concentration of VMA was calculated from the VMA/iso-VMA peakheight ratios in the sample extract and in the calibration mixture (1 pmol/L VMA and 4 moIJL iso-VMA in mobile phase).
During the first 3 years of the study period, a slightly different extraction procedure with external standardization was used (15). The modification was introduced for practical reasons and affected neither the accuracy nor the precision of the assay.
Urinary metanephrunes
were extracted from 2-mL aliquots after acid hydrolysis.
Sample purification was performed by using commercially available cation-and anion-exchange columns (Bio-Rad Labs., Richmond, CA). The 
Reference Values
The upper reference limits for urinary catecholamines and VMA, listed under Table 1 , were previously determined in our laboratory (15, 16) and correspond to the 97.5 percentiles of a population that included hypertensive patients. Using the same criteria, we determined reference limits for urinary metanephrunes in a population of 60 men and 105 women. The reference limits for plasma catecholamines were taken from the literature (17).
Statistical Methods
The correlation of excretion values in patients with pheochromocytoma was evaluated with the nonparametric Spearman rank test (Statview SE+ statistical package; Abacus Concepts, Berkeley, CA).
Results
Preoperative
data for the excretion rates in our 19 pheochromocytoma patients and for plasma catecholamines in 10 of them are presented in CVs were: 22% (1-61%) for urinary NE; 24% (0-85%) for urinary E; 17% (0-35%) for NMN; 15% (1-34%) for MN; 20% (2-39%) for VMA 28% (9-67%) for plasma NE; and 31% (5-72%) for plasma E. These data illustrate that the largest fluctuations were observed for plasma catecholamines and the smallest fluctuations for urinary metanephrines.
The differences, however, were small and, because the number of patients and the number of samples for each patient were not the same for the various analytes, no definite conclusions should be drawn about the relative intraindividual variability of the different analytes. However, the consistency of the excretion patterns, evident from the multiple samplings, underlies the classification of the patients as given in Table 1 .
Urinary Metabolites
Based on the amounts of NE and E excreted, four patterns can be distinguished.
In seven patients (37%), the values for both NE and E were more than threefold the upper reference limit (group A). Such values are never observed in other disease processes that activate the sympathoadrenal axis; they can thus be considered as diagnostic of pheochromocytoma. Four patients (2 1%) had markedly increased excretion of NE with normal or only slightly increased E values (group B). Five patients (26%) had predominantly E-secreting tumors: E values were more than sixfold the upper reference limit, while NE was at the upper limit of normal or only slightly increased (group C). In three patients (16%), neither NE nor E was markedly increased (group D). One of these patients was normotensive (patient
another had paroxysmal hypertension (patient 18). The third patient in this group had a slight increase of urinary E (patient 19) and was diagnosed to have MEN-I!. In the whole group of 19 patients, the rank correlation between NE and E values was not statistically significant ( Table 2 ). The excretion of NMN exceeded threefold the upper reference limit in all patients with markedly increased NE (groups A and B) . Metanephrine was at least threefold the upper reference limit in all patients with markedly increased E concentration (groups A and C). Fig. 1 . Fig. 2 illustrates the excellent correlation between VMA and total metanephrines. Table 3 summarizes the results of the 24-h urine measurements.
The diagnostic sensitivity was the highest for the assay of individual metanephrines (100%) and the lowest for the assay of VMA (84%). The increase of individual catecholamines and metanephrines was usually more pronounced than the increase of VMA.
Plasma Catecholamines
Plasma concentrations of NE or E were increased in patients with increased urinary excretion of NE or E, respectively ( 19 ). In the patient with MEN-I!, concentrations were increased after a glucagon provocative test (Fig. 3) .
Discussion
Pheochmmocytoma is diagnosed during life in fewer than half of the patients in whom it is found at autopsy The data poIntcorresponding to patient118out of scale and was omitted In the calculationof the regressionequation. 
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The high prevalence of tumors found at autopsy suggests that the usual diagnostic criteria need to be reevaluated (8). The demonstration of excessive catecholamine production is considered essential in the diagnosis. Many different tests are available, but the optimal strategy for identifying patients with pheochromocytoma remains controversial (19). The diagnostic sensitivity of a particular test reported by a single institution will depend on the assay method, the upper reference limit for this method in the laboratory, the expertise of the technicians performing the tests, the care with which samples are collected, and the characteristics of the patients. Laboratories using assays with poor analytical specificity will use a high upper reference limit to avoid the problem of false positives at the expense of lower diagnostic sensitivity (e.g., 1). The percentage of patients with MEN-il or other purely E-secreting tumors in a given series of pheochromocytoma will affect the reported sensitivity of a particular test.
In our study all measurements 6) ; VMA, 66 for both sexes. In 68% of our patients (13 of 19), the amounts of urinary catecholamines and metabolites were so high that the pheochromocytoma could have been diagnosed by using any of the three urinary tests (all patients from groups A and B and two patients from group C). However, not all patients with pheochromocytoma excrete large quantities of all metabolites: e.g., patients
with pure E-secreting tumors or MEN-I! and asymptomatic patients. Diagnosing these patients presents a real challenge to the dlinican as well as the laboratory;
for these patients, the choice of a screening test may be of utmost importance. We agree with these authors and others (5) that the assays of total catecholamines and total metanephrines are diagnostically inadequate, and that NE and E, and NMN and MN, should be measured separately.
Until recently
Specific and sensitive assays forE or MN are thus essential for finding some of the pure E-secreting tumors. Combined assays diminish the impact of E or MN and may be the cause of false negatives. It is also important to note that hypertension may not be manifest in patients harboring predominantly E-secreting tumors (5, 8,21,22) .
In a report from the Mayo Clinic (23), only 54% of the patients in whom pheochromocytoma was diagnosed at autopsy were known to have had hypertension.
These observations indicate that the absence of hypertension cannot be a criterion for excluding the diagnosis of pheochromocytoma in patients with suggestive symptoms such as headache, perspiration, and palpitations.
The specific measurement of E in urine is valuable in the diagnosis of MEN-il-associated pheochromocytoma. A slight increase in E may be either the dominant or the sole abnormal finding in the catecholamine excretion pattern and may be diagnostic of the presence of a pheochromocytoma (24, 25) . This was the case in our only patient with this condition 10-fold, whereas E was increased 2.5-fold. In another case (27), the increase of total metanephrines was more marked than that of E (16-fold vs 2.5-fold). In our patient, the elevation of MN was only slightly more marked than that of E (1.7-fold vs 1.3-fold). Considering that MN was increased to the same degree as E or even more in other patients with pure E-secreting tumors (group C), the assay of individual metanephrines might be as valuable as the assay of individual catecholamines in identifying patients with MEN-H. Two patients, cases 17 and 18, had normal NE and E excretion and no symptoms or signs suggestive of pheochromocytoma.
However A and B) . In our 5 patients with pure E-secreting tumors (group C), plasma E was increased two-to fourfold, and total catecholamines ranged from 4.0 to 8.4 nmoljl4, emphasizing the necessity to consider NE and E individually.
In all these cases, the increase of urinary E (4-to 11-fold) was more marked than that of plasma E (<4-fold). for patients with suggestive symptoms, and for asymptomatic patients in whom a "clinically silent" unsuspected adrenal mass has been incidentally detected.
Because our HPLC assay for fractionated urinary catecholamines has the advantage of being less time-consuming, cheaper, and more precise than our assay for fractionated metanephrines, we consider the former to be our best choice for the evaluation of patients with suggestive symptoms; however, it should not be used for the initial evaluation of patients with an incidentally discovered adrenal mass. The assay of urinary VMA does not yield additional diagnostic information to that determined for urinary metanephrines and may fail to detect predominantly E-secreting tumors.
In conclusion, the assay of plasma catecholamines should be considered only as a last resort in conjunction with pharmacological testing. We emphasize that pure E-secreting tumors may be relatively common and that specific assay procedures are essential for the diagnosis of such tumors. We argue against the measurement of total catecholamines, total metanephrines, and VMA in the diagnosis of pheochromocytoma.
We believe that the widespread use of these outmoded analytical procedures is a major reason why many pheochromocytoma remain undiagnosed prior to surgery or autopsy.
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